2015
DOI: 10.1016/j.jconrel.2015.03.024
|View full text |Cite
|
Sign up to set email alerts
|

Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
30
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
4
3
3

Relationship

1
9

Authors

Journals

citations
Cited by 62 publications
(30 citation statements)
references
References 233 publications
0
30
0
Order By: Relevance
“…However, the kinetics of CXCL12 released from NPs delivery systems are rarely characterized using mathematical modeling. Such an experimental approach is important not only to better understand the phenomena that control the chemokine delivery but also help to optimize and calibrate the delivery to the desired parameters [10,27]. For example, we have previously developed a composite NPs delivery system made of alginate (Alg) and chitosan (Chit) to encapsulate a positively charged peptide derived from bone morphogenetic protein-9 (SpBMP-9, 23 residues) for brain application.…”
Section: Introductionmentioning
confidence: 99%
“…However, the kinetics of CXCL12 released from NPs delivery systems are rarely characterized using mathematical modeling. Such an experimental approach is important not only to better understand the phenomena that control the chemokine delivery but also help to optimize and calibrate the delivery to the desired parameters [10,27]. For example, we have previously developed a composite NPs delivery system made of alginate (Alg) and chitosan (Chit) to encapsulate a positively charged peptide derived from bone morphogenetic protein-9 (SpBMP-9, 23 residues) for brain application.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, it was suggested that patients were treated too late, having irreversible brain damage 10–20 years after onset of the disease, explaining the discrepancy with promising studies using animal models of AD (Mullane and Williams, 2013 ). Importantly, clinical failure of therapeutic agents was explained by low bioavailability in the CNS due to restriction by the blood–brain barrier (BBB) (Lauzon et al, 2015 ). In order to develop effective therapies for AD, much effort is needed to increase our knowledge of the involved disease pathways and to develop suitable drug delivery systems.…”
Section: Current Treatmentmentioning
confidence: 99%
“…Capillary flow, binding, structure, and BBB permeability changes may confound the dosing-design strategy. 100 Without an endogenous biomarker signaling response, measuring the effectiveness with these approaches is limited.…”
Section: Innovative Drug Deliverymentioning
confidence: 99%